BRPI0600796B8 - forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo - Google Patents

forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo

Info

Publication number
BRPI0600796B8
BRPI0600796B8 BRPI0600796A BRPI0600796A BRPI0600796B8 BR PI0600796 B8 BRPI0600796 B8 BR PI0600796B8 BR PI0600796 A BRPI0600796 A BR PI0600796A BR PI0600796 A BRPI0600796 A BR PI0600796A BR PI0600796 B8 BRPI0600796 B8 BR PI0600796B8
Authority
BR
Brazil
Prior art keywords
crystalline form
gamma
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
BRPI0600796A
Other languages
English (en)
Inventor
Damien Gérard
Auguste Marie-Noëlle
Horvath Stéphane
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0600796(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0600796A publication Critical patent/BRPI0600796A/pt
Publication of BRPI0600796B1 publication Critical patent/BRPI0600796B1/pt
Publication of BRPI0600796B8 publication Critical patent/BRPI0600796B8/pt

Links

Classifications

    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo. a presente invenção refere-se a uma forma y-cristalina de cloridrato de ivabradina de fórmula (i): caracterizada por seu diagrama de difração de raios x no pó. medicamentos.
BRPI0600796A 2005-02-28 2006-02-24 forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo BRPI0600796B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR0501989 2005-02-28

Publications (3)

Publication Number Publication Date
BRPI0600796A BRPI0600796A (pt) 2007-08-14
BRPI0600796B1 BRPI0600796B1 (pt) 2019-02-19
BRPI0600796B8 true BRPI0600796B8 (pt) 2021-05-25

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0600796A BRPI0600796B8 (pt) 2005-02-28 2006-02-24 forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo

Country Status (42)

Country Link
US (3) US7361650B2 (pt)
EP (1) EP1707562B1 (pt)
JP (1) JP4628974B2 (pt)
KR (1) KR100835447B1 (pt)
CN (1) CN100402502C (pt)
AP (1) AP1956A (pt)
AR (1) AR052926A1 (pt)
AT (1) ATE396974T1 (pt)
BR (1) BRPI0600796B8 (pt)
CA (1) CA2537400C (pt)
CO (1) CO5770097A1 (pt)
CR (1) CR8249A (pt)
CU (1) CU23616B7 (pt)
CY (1) CY1109010T1 (pt)
DE (1) DE602006001312D1 (pt)
DK (1) DK1707562T3 (pt)
EA (1) EA008465B1 (pt)
ES (1) ES2308689T3 (pt)
FR (1) FR2882555B1 (pt)
GE (1) GEP20084467B (pt)
GT (1) GT200600088A (pt)
HK (1) HK1096659A1 (pt)
HR (1) HRP20080406T5 (pt)
IL (1) IL173959A0 (pt)
JO (1) JO2515B1 (pt)
MA (1) MA28134A1 (pt)
ME (1) ME02747B (pt)
MY (1) MY158129A (pt)
NO (1) NO338481B1 (pt)
NZ (1) NZ545578A (pt)
PE (1) PE20061142A1 (pt)
PL (1) PL1707562T3 (pt)
PT (1) PT1707562E (pt)
RS (1) RS50598B (pt)
SA (1) SA06270040B1 (pt)
SG (1) SG125229A1 (pt)
SI (1) SI1707562T1 (pt)
TW (1) TWI314143B (pt)
UA (1) UA86595C2 (pt)
UY (1) UY29406A1 (pt)
WO (1) WO2006092492A1 (pt)
ZA (1) ZA200601764B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
ATE544754T1 (de) 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
JP5632279B2 (ja) 2007-05-30 2014-11-26 アイエヌディー−スイフト ラボラトリーズ リミテッド 塩酸イバブラジンの調製方法及びポリモルフ
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
HUE035588T2 (en) 2010-02-12 2018-05-28 Krka D D Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2780327A1 (en) 2011-11-14 2014-09-24 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
FI2781509T4 (fi) * 2013-03-19 2023-09-07 Ivabradiinihydrokloridin uusi polymorfi ja sen valmistusmenetelmä
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es) 2013-12-12 2019-03-20 Synthon Bv Composicion farmaceutica que comprende ivabradina amorfa.
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CR8249A (es) 2008-01-21
ME02747B (me) 2010-05-07
CA2537400C (fr) 2009-12-15
AP1956A (en) 2009-02-18
NZ545578A (en) 2007-02-23
GT200600088A (es) 2006-10-24
BRPI0600796A (pt) 2007-08-14
NO338481B1 (no) 2016-08-22
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
AU2006200857A1 (en) 2010-01-28
TW200640872A (en) 2006-12-01
CU23616B7 (es) 2011-01-27
TWI314143B (en) 2009-09-01
BRPI0600796B1 (pt) 2019-02-19
ZA200601764B (en) 2007-05-30
MA28134A1 (fr) 2006-09-01
US7867996B2 (en) 2011-01-11
US20060194963A1 (en) 2006-08-31
WO2006092492A1 (fr) 2006-09-08
CN1827602A (zh) 2006-09-06
JP2006241156A (ja) 2006-09-14
EA008465B1 (ru) 2007-06-29
JP4628974B2 (ja) 2011-02-09
PT1707562E (pt) 2008-07-08
ES2308689T3 (es) 2008-12-01
FR2882555B1 (fr) 2007-05-04
US20090318417A1 (en) 2009-12-24
DK1707562T3 (da) 2008-10-13
AR052926A1 (es) 2007-04-11
EP1707562B1 (fr) 2008-05-28
MY158129A (en) 2016-08-30
CO5770097A1 (es) 2007-06-29
UY29406A1 (es) 2006-07-31
DE602006001312D1 (de) 2008-07-10
IL173959A0 (en) 2006-07-05
UA86595C2 (ru) 2009-05-12
EP1707562A1 (fr) 2006-10-04
US20080153803A1 (en) 2008-06-26
AP2006003521A0 (en) 2006-02-28
SG125229A1 (en) 2006-09-29
SA06270040B1 (ar) 2010-03-23
CY1109010T1 (el) 2014-07-02
PL1707562T3 (pl) 2008-08-29
US7361650B2 (en) 2008-04-22
JO2515B1 (en) 2010-03-17
NO20060948L (no) 2006-08-29
HK1096659A1 (en) 2007-06-08
EA200600320A1 (ru) 2006-08-25
KR20060095499A (ko) 2006-08-31
PE20061142A1 (es) 2006-12-30
CU20060037A7 (es) 2008-06-30
SI1707562T1 (sl) 2008-10-31
ATE396974T1 (de) 2008-06-15
GEP20084467B (en) 2008-08-25
HRP20080406T3 (en) 2008-09-30
RS50598B (sr) 2010-05-07
KR100835447B1 (ko) 2008-06-09
FR2882555A1 (fr) 2006-09-01
HRP20080406T5 (en) 2008-11-30

Similar Documents

Publication Publication Date Title
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0604253A (pt) forma deltad-cristalina de cloridrato de ivabradina, um processo para sua preparação e composições farmacêuticas contendo-as
BRPI0600696A (pt) forma gamad-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0600623A (pt) forma beta-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
ECSP066915A (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmaceuticas que la contienen
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
CU20060195A7 (es) Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmacéuticas que lo contienen
CU20060193A7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen
UY29855A1 (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
JO2501B1 (en) The crystalline form of gamma-D of ivabradine hydrochloride, its preparation process and its pharmaceutical ingredients

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF